Several studies such as IDNT (Irbesartan Diabetic Nephropathy Trial), RENAAL (Reduction in End-Points in Noninsulin-Dependent Diabetes Mellitus with the Ang-II Antagonist Losartan), IRMA-2 (Effect of Irbesartan in the Development of Diabetic Nephropathy in Patients with T2DM), ROADMAP (Randomized Olmesartan and Diabetes Microalbuminuria Prevention), and the Captopril study all demonstrated inhibition of DN progression [163]. The gene discussed is AGT; the disease is diabetes mellitus.